OpGen is a medical devices business based in the US. OpGen shares (OPGN) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $1.99 – an increase of 5.85% over the previous week.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.99 |
|---|---|
| 52-week range | $1.40 - $9.90 |
| 50-day moving average | $1.85 |
| 200-day moving average | $3.41 |
| Wall St. target price | $3.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-40.32 |
Historical closes compared with the close of $1.95 from 2024-11-18
| 1 week (2024-11-13) | 31.31% |
|---|---|
| 1 month (2024-10-18) | 11.43% |
| 3 months (2024-08-20) | -18.75% |
| 6 months (2024-05-20) | -49.48% |
| 1 year (2023-11-20) | 333.24% |
|---|---|
| 2 years (2022-11-18) | -95.55% |
| 3 years (2021-11-19) | 308 |
| 5 years (2019-11-20) | 204 |
| Revenue TTM | $2 million |
|---|---|
| Gross profit TTM | $-8,990,133 |
| Return on assets TTM | -43.25% |
| Return on equity TTM | -314.92% |
| Profit margin | 0% |
| Book value | $-8.65 |
| Market Capitalization | $15.7 million |
TTM: trailing 12 months
We're not expecting OpGen to pay a dividend over the next 12 months.
OpGen's shares were split on a 1:10 basis on 19 May 2024 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your OpGen shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for OpGen shares which in turn could have impacted OpGen's share price.
Over the last 12 months, OpGen's shares have ranged in value from as little as $1.4 up to $9.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while OpGen's is -0.598. This would suggest that OpGen's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, OpGen has bucked the trend.
OpGen, Inc. , a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. OpGen, Inc. was incorporated in 2001 and is headquartered in Rockville, Maryland. .
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.